Pilot Projects and Infrastructure. We are requesting $150,000/year to support 3-5 pilot projects for 1-2 years at an annual cost of $25,000 - $50,000 per investigator. This is an amount and time sufficient for an investigator to mount a truly new initiative and obtain sufficient preliminary data for an NCI grant application or a Clinical Trial. Smaller amounts of money, in our experience, permit only an incremental extension of on-going work. Although a budget breakdown would vary considerably from one project to another, depending on the nature of the research, these funds would typically cover personnel costs of a post-doc or technician at 50 -100% time, plus supplies and animals. Requests for new or improved infrastructure are generally handled through the Pilot Project process, and are weighed against the opportunities for new research initiatives. No faculty salaries are supported with Pilot Project monies. We will use institutional and philanthropic funds totaling $350,000 to bring the total funding base for internal pilot projects and infrastructure to $500,000. This is more than a 2 to 1 matching of the CCSG pilot funds with philanthropic funds. Our ability to raise these philanthropic funds is explicitly based on leveraging the investment made by the NCI in this activity, through the allocation of Developmental funding. Our experience has been that the NCI funding provides credibility for philanthropists, and that donors are more willing to provide research support when it is on top of an NCI investment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-19
Application #
7771651
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
19
Fiscal Year
2009
Total Cost
$205,461
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148

Showing the most recent 10 out of 539 publications